Equity in edge situations: access to treatment for people with hemophilia
Keywords:Hemophilia, Rare diseases, Bioethics, Equity, Justice
Hemophilia is a rare hematological condition, and its treatment is a target of therapeutic innovation. In the encounter between the patient's needs, the clinician's behavior, and the health manager's orientation, the conflict arises: is the clinical protocol a minimum or maximum? The clinical decisions in a debate with the allocation of resources lead to the discussion about equity in these edge situations. The method of the present study is comprehensive, based on a bioethical analysis of 14 court decisions regarding access to hemophilia treatments. Decisions to guarantee access to treatments presuppose an ethical link with the patient; the clinic maintains a dimension of equity allowing that treatment to be singular, and the doses provided for in the protocol are suggestions and no limits. From an ethical point of view, these are expressions of justice, precaution, and consider the patient's interests.
- 10/26/2020 (2)
- 10/19/2020 (1)
How to Cite
Copyright (c) 2020 Andréa Carolina Lins de Góes, Daniela Amado Rabelo, Tiago Félix Marques, Natan Monsores
This work is licensed under a Creative Commons Attribution 4.0 International License.